[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354215-105":59,"doc-detail-354215-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","mechanism-and-therapeutic-potential-of-viral-mimicry-in-cancer-immunotherapy","Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy","","Cancer immunotherapy harnesses immune recognition to eliminate malignant cells, yet many tumors respond poorly due to limited antigen presentation and disrupted interferon (IFN) signaling, producing an immunologically “cold” tumor microenvironment with weak immune infiltration and resistance. Viral mimicry aims to reactivate innate antiviral pathways inside tumor cells by engaging endogenous retroviruses and other retrotransposons that trigger nucleic acid sensing. Type I/III IFN activation can restore antigen presentation, recruit cytotoxic immunity, and sensitize resistant disease. Because systemic pathway stimulation may drive inflammation and adaptive resistance, temporal and spatial control is essential. This review synthesizes mechanisms and clinical development, highlighting opportunities for combination with established therapies and engineered immune platforms.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mechanism-and-therapeutic-potential-of-viral-mimicry-in-cancer-immunotherapy/354215/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mechanism-and-therapeutic-potential-of-viral-mimicry-in-cancer-immunotherapy/354215.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"What are the main risks of activating these IFN pathways systemically?","Question",{"text":113,"@type":114},"Systemic stimulation can trigger context-dependent inflammation and adaptive resistance, making temporal and spatial control necessary to preserve therapeutic benefit.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},354215,1790264222,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":132,"language":133,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":134,"faqs":135,"seo_title":136,"seo_description":67,"update_tm":137,"read_time":138,"preview_page_count":19,"preview_urls":139},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nMechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy  \nAlisha Pearl Kirkland , Mahek Shah  and Charles Spruck *  \nAcademic Editor: Chang Liu  \nReceived: 11 April 2026  \nRevised: 4 May 2026  \nAccepted: 7 May 2026  \nPublished: 12 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nCancer Genome and Epigenetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA  \n* Correspondence: [cspruck@sbpdiscovery.org](cspruck@sbpdiscovery.org)  \nAbstract  \nCancer immunotherapy has transformed oncology by harnessing the immune system to recognize and eliminate malignant cells. However, many cancers exhibit limited or variable responses to this class of treatment due to insufficient antigen presentation and impaired interferon (IFN) signaling, creating an immunologically “cold” tumor microenvironment (TME) characterized by poor immune cell infiltration and treatment resistance. Viral mimicry has emerged as a therapeutic strategy to overcome these limitations by reactivating innate antiviral pathways within tumor cells. Viral mimicry occurs through thereactivation of endogenous retroviruses (ERVs) and other retrotransposons (e.g., LINE-1), which subsequently stimulate downstream nucleic acid sensing pathways. The resulting type I/III IFN responses restore antigen presentation and attract cytotoxic immune cells, sensitizing resistant tumors to immunotherapy. However, systemic stimulation of these pathways can trigger context-dependent inflammation and adaptive resistance, highlighting the need for temporal and spatial control. In this review, we examine the mechanistic foundation and clinical trajectory of viral mimicry, with an emphasis on its potential integration with established treatments and engineered immune cell platforms. By identifying the molecular and clinical gaps, viral mimicry can be harnessed to enhance tumor-specific immune activation and overcome treatment resistance in cancer immunotherapy.  \nKeywords: cancer immunotherapy; repetitive elements; viral mimicry; innate immunity; adaptive immunity; epigenetic alteration; genomic instability; neoantigens; chimeric antigen receptor; natural killer cells; T cells; clinical trials  \n1. Introduction  \nCancer is the second leading cause of mortality worldwide, with global incidence projected to exceed 35.3 million cases by 2050 [1,2] . Over the past decade, immune checkpoint blockade (ICB) therapy has reshaped the treatment landscape by improving immunemediated tumor surveillance. Following the U.S. Food and Drug Administration’s (FDA) approval of the first-in-class cytotoxic T lymphocyte antigen 4 (CTLA-4) checkpoint inhibitor for metastatic melanoma in 2011 [3], additional agents targeting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and lymphocyte activation gene 3 (LAG-3) have produced durable clinical benefits across a range of malignancies [4] . Despite these advances, therapeutic responses remain highly variable and many patients experience immune-related adverse events (irAEs) resulting from systemic immune activation [5–10] . Moreover, emerging evidence suggests that sustained IFN signaling can promote immune dysfunction and resistance, further narrowing the therapeutic  \nwindow of opportunity for ICB-based approaches. These limitations underscore the need for complementary strategies that enhance their efficacy while minimizing toxicity.  \nOne of the principal barriers to effective ICB therapy is an immunosuppressive TME. The TME is composed of a heterogeneous network of immune and stromal elements, including lymphocytes, cancer-associated fibroblasts (CAFs), endothelial cells, and extracellular matrix (ECM) components, that sustain tumor persistence and immune evasion [11] . Tumorintrinsic features such as stroma","cbCaiagLANzYz5A4","https://ap.wps.com/l/cbCaiagLANzYz5A4","pdf",4656568,33,"English","# Introduction\n## Immunotherapy efficacy and variability\n## Tumor microenvironment barriers and immunophenotypes\n## Immune regulation and epigenetic suppression","[{\"question\":\"What are the main risks of activating these IFN pathways systemically?\",\"answer\":\"Systemic stimulation can trigger context-dependent inflammation and adaptive resistance, making temporal and spatial control necessary to preserve therapeutic benefit.\"}]","Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy | PDF",1790109546,83,[140,144,148,152],{"page_no":8,"url":141,"width":142,"height":143},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90bc519459b961adb18a8b6d80aa7945.webp",983,1390,{"page_no":14,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87a7d848445407dcf850b78c08d5e710.webp",982,1388,{"page_no":81,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d605982db4e04ce47467afc07b08ae5f.webp",981,1387,{"page_no":19,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/543debfb041811779628a5285666255e.webp",980,1385]